MIA in the spotlight at ASCO virtual conference
30 May 2020
This year’s American Society of Clinical Oncology (ASCO) Annual Meeting has gone virtual, with researchers from MIA once again in the spotlight. Usually attended by over 40,000 professionals, ASCO’s Annual Meeting showcased global advances in research and treatment, all of which impact patient outcomes.
Headlining MIA’s contribution at ASCO 20 Virtual was Dr Ines Silva, a clinical fellow and post-doctoral researcher at MIA, who was awarded the prestigious Bradley Stuart Beller Endowed award for best abstract.
Dr Silva’s abstract related to an oral presentation delivered virtually at ASCO, assessing the impact of Ipilimumab-based immunotherapy in patients with metastatic melanoma whose disease had already proven resistant to anti-PD1 monotherapy.
The multicentre retrospective study involved 355 patients with Stage III or Stage IV melanoma whose cancer had progressed or recurred despite having anti-PD1 monotherapy. 46% of these patients were then treated with ipilimumab alone, with 54% receiving combination ipilimumab and anti-PD1 therapy.
In patients who received the follow up combination therapy, there was a higher response rate (32%) as well as longer progression free survival (25% at 12 months) and overall survival (58% at 12 months) compared to IPI alone. Importantly, IPI+anti-PD1 was not associated with more severe side effects than IPI monotherapy.
Dr Silva and the MIA team created clinical predictive models to help identify the patients who will benefit from these treatments.
‘It was an honour to deliver the oral presentation virtually at ASCO 20 Virtual,’ said Dr Silva. ‘Although we weren’t together physically, still being able to share insights and learnings globally was vitally important in ensuring we continue on our path to saving more lives from melanoma.’
Also awarded at ASCO 20 Virtual were Dr Adriana Hepner and Dr Lauren Brown who received merit awards for abstracts submitted. Overall, MIA researchers and clinicians contributed to 21 abstracts featured at ASCO.
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way in changing the treatment landscape for melanoma patients,’ MIA Co-Medical Director Professor Georgina Long said.
‘Our mission is zero deaths from melanoma, and by collaborating with our colleagues on the world stage we are confident we are on track to reach that goal within our lifetime,’ added MIA Co-Medical Director Professor Richard Scolyer.
Register to view Dr Silva's video and slides here: Dr Silva presentation
See the ASCO 20 Virtual Program here: ASCO 20 Virtual
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.
Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.
Throughout January our community created, hosted and participated in some amazing events, each of them helping us on our quest to reach zero deaths from melanoma.
Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.
Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.